Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Parker Institute for Cancer Immunotherapy
Biotech
Tessa Therapeutics dissolves after raising more than $200M
Tessa Therapeutics is closing its doors after failing to woo new investors as it pursued a suite of cell therapies.
Max Bayer
Jul 6, 2023 11:55am
LumaBridge inks deal with PICI for immunotherapy development
Aug 31, 2022 9:30am
Former Takeda exec takes reins at Tessa—Chutes & Ladders
Aug 26, 2022 9:30am
Seres stops microbiome cancer trial, deprioritizes drug
Mar 8, 2021 8:40am
Parker Institute names Connolly as CSO, targets biopharma pacts
Jul 24, 2020 7:55am
